Bundó, Magdalena
Vlacho, Bogdan
Llussà, Judit
Bobé, Isabel
Aivar, Meritxell
Ciria, Carmen
Martínez‐Sánchez, Ana
Real, Jordi
Mata‐Cases, Manel
Cos, Xavier
Dòria, Montserrat
Viade, Jordi
Franch‐Nadal, Josep http://orcid.org/0000-0002-5175-1555
Mauricio, Dídac http://orcid.org/0000-0002-2868-0250
Funding for this research was provided by:
Primary Care Diabetes Europe (PCDE2019/4)
Article History
Received: 2 March 2022
Accepted: 16 January 2023
First Online: 28 February 2023
Declarations
:
: The study was approved by the IDIAP Jordi Gol Ethics Committee (protocol approval number P16 / 127), and all included participants signed a written informed consent form.
: Not applicable.
: Manel Mata-Cases has received advisory and/or speaking fees from Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, MSD, NOVARTIS, NovoNordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, NovoNordisk, and Sanofi; he has received research grants from Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol) (Barcelona, Spain), Instituto de Salud Carlos III (Madrid, Spain), Generalitat de Catalunya. Peris 2016–2020. The Strategic Plan for Health Research and Innovation (Barcelona, Spain).Josep Franch-Nadal has received advisory and/or speaking fees from Astra-Zeneca, Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, NovoNordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, NovoNordisk, Sanofi, and Boehringer.Dídac Mauricio has received advisory and/or speaking fees from Astra-Zeneca, Ascensia, Boehringer Ingelheim, Lilly, MSD, NovoNordisk, and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, NovoNordisk, Sanofi, and Boehringer.Magdalena Bundó, Judit Llussà, Isabel Bobé, Meritxell Aivar, Carmen Ciria, Ana Martínez-Sánchez have received advisory and speaking fees from MSD.Xavier Cos has received speaker's bureau and advisory board honoraria from AstraZeneca, Boehringer Ingelheim, Esteve, Lilly Diabetes, Novo Nordisk A/S, Roche, and Sanofi.Jordi Real, Montserrat Dòria, Jordi Viade, and Bogdan Vlacho have no conflicts of interest to declare.